Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest update is out from Haleon PLC ( (GB:HLN) ).
Haleon PLC has completed the acquisition of an additional 33% equity interest in its China-based joint venture, Tianjin TSKF Pharmaceutical Co. Ltd, for approximately £0.5 billion. This move, which follows shareholder approval and necessary clearances, strengthens Haleon’s market position in China and is expected to be accretive to its earnings per share (EPS), indicating a positive impact on its financial performance and a strategic expansion in the Chinese market.
More about Haleon PLC
Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health through a diverse portfolio in categories such as Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals and Supplements. The company is known for its trusted brands like Advil, Sensodyne, and Centrum, which are built on scientific innovation and human understanding.
YTD Price Performance: 18.44%
Average Trading Volume: 21,361,093
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £33.87B
For an in-depth examination of HLN stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Amazon (NASDAQ:AMZN) Carries on With Grocery Store Plans
- Ford (NYSE:F) Faces Multiple Product Recalls
- ‘Favorable Trends,’ Says Top Investor About Super Micro Computer Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
